{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:37:48Z","timestamp":1783359468213,"version":"3.54.6"},"reference-count":22,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Prospective trials provide robust evidence for prostate cancer (PCa) treatment but often include highly selective populations, limiting generalizability. Real-world data (RWD) can address these gaps and inform personalized care. Objectives: This study aimed to evaluate treatment-free survival (TFS) and secondary treatment sequences after initial curative therapy for PCa using electronic health record (EHR) data and to analyze associated medication profiles. Methods: We studied 3024 patients treated with radical prostatectomy (RP), brachytherapy (BT), or curative radiotherapy (RT) at Erasmus MC (2009\u20132023), the Netherlands. Outcomes included TFS, treatment sequences, and medication patterns across treatment lines. Results: Median age at diagnosis was 65 years (IQR 61\u201369) for RP, 68 (62\u201373) for BT, and 72 (68\u201376) for RT. At 10 years, TFS was 89% (95% CI: 84.9\u201394.1) for BT, 85% (95% CI: 83\u201387) for RT, and 71% (95% CI: 65.7\u201375.8) for RP. Most patients remained treatment-free, but up to five treatment lines occurred, mainly in patients with low comorbidity scores. Medication profiles reflected treatment-related morbidity: alpha-blocker use increased after BT and RT, while bladder relaxants were common after RP. Comorbidity-related medication use remained low among patients undergoing multiple sequenced treatments. Conclusions: These findings highlight the real-world application of multiple secondary treatments after different primary curative therapy options for PCa and associated comorbidity and medication use patterns. They confirm the durability and long-term effectiveness of curative treatments in real-world PCa care. By combining treatment trajectories and medication profiles, RWD provides insights for personalized counseling, helping clinicians and patients anticipate long-term treatment needs, and enabling informed decisions aligned with health status and preferences.<\/jats:p>","DOI":"10.3390\/jpm16010022","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:03:48Z","timestamp":1767607428000},"page":"22","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment-Free Survival and the Pattern of Follow-Up Treatments After Curative Prostate Cancer Treatment, a Real-World Analysis of Big Data from Electronic Health Records from a Tertiary Center"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3306-9297","authenticated-orcid":false,"given":"Fr\u00e9derique B.","family":"Denijs","sequence":"first","affiliation":[{"name":"Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-6448","authenticated-orcid":false,"given":"Sebastiaan","family":"Remmers","sequence":"additional","affiliation":[{"name":"Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard P.","family":"Bokhorst","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Haaglanden Medical Center, 2512 The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C. N.","family":"van den Bergh","sequence":"additional","affiliation":[{"name":"Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6967-1708","authenticated-orcid":false,"given":"Monique J.","family":"Roobol","sequence":"additional","affiliation":[{"name":"Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","article-title":"Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial","volume":"104","author":"Pasalic","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","article-title":"Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival","volume":"110","author":"Heemsbergen","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Holmberg","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials\u2014The gold standard for effectiveness research: Study design: Randomised controlled trials","volume":"125","author":"Hariton","year":"2018","journal-title":"BJOG"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.eururo.2025.07.001","article-title":"Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer","volume":"88","author":"Holmberg","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19113","DOI":"10.1038\/s41598-024-70292-y","article-title":"Clinical decision making in prostate cancer care\u2014Evaluation of EAU-guidelines use and novel decision support software","volume":"14","author":"Engesser","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40537-021-00553-4","article-title":"The use of Big Data Analytics in healthcare","volume":"9","author":"Batko","year":"2022","journal-title":"J. Big Data"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41585-023-00748-9","article-title":"Unanswered questions in prostate cancer\u2014Findings of an international multi-stakeholder consensus by the PIONEER consortium","volume":"20","author":"Omar","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/EDE.0000000000001358","article-title":"An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate Cohorts","volume":"32","author":"Gedeborg","year":"2021","journal-title":"Epidemiology"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"van Oostrom, S.H., Picavet, H.S., van Gelder, B.M., Lemmens, L.C., Hoeymans, N., van Dijk, C.E., Verheij, R.A., Schellevis, F.G., and Baan, C.A. (2012). Multimorbidity and comorbidity in the Dutch population\u2009\u2013\u2009data from general practices. BMC Public Health, 12.","DOI":"10.1186\/1471-2458-12-715"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5694\/mja2.50966","article-title":"Patterns of care for men with prostate cancer: The 45 and Up Study","volume":"214","author":"Yap","year":"2021","journal-title":"Med. J. Aust."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114072","DOI":"10.1016\/j.ejca.2024.114072","article-title":"Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland\u2014A claims data analysis","volume":"204","author":"Stucki","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Beyer, K., Straten, V., Remmers, S., MacLennan, S., MacLennan, S., Gandaglia, G., Willemse, P.-P.M., Herrera, R., Omar, M.I., and Russell, B. (2022). Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform. J. Pers. Med., 12.","DOI":"10.3390\/jpm12050751"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.euros.2024.06.007","article-title":"Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma","volume":"66","author":"Bhavsar","year":"2024","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5489\/cuaj.3288","article-title":"Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia","volume":"9","author":"Peacock","year":"2015","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12589","DOI":"10.1038\/s41598-022-16395-w","article-title":"Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: A 10-year follow-up cohort study","volume":"12","author":"Zamora","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.urology.2010.01.010","article-title":"Five Year Biochemical Recurrence Free Survival for Intermediate Risk Prostate Cancer After Radical Prostatectomy, External Beam Radiation Therapy or Permanent Seed Implantation","volume":"76","author":"Vassil","year":"2010","journal-title":"Urology"},{"key":"ref_22","unstructured":"(2024, November 30). AU UroEvidenceHub Launches Prospective Prostate Cancer Data Registry with First Patient Successfully Added. Available online: https:\/\/uroweb.org\/science-publications\/eau-uroevidencehub."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/1\/22\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:20:40Z","timestamp":1767608440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/1\/22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jpm16010022"],"URL":"https:\/\/doi.org\/10.3390\/jpm16010022","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]}}}